Top

Published in:

Open Access 01-12-2022 | Amyotrophic Lateral Sclerosis | Review

The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A

Authors: Jiajia Fu, Yan Huang, Ting Bao, Chengcheng Liu, Xi Liu, Xueping Chen

Published in: Journal of Neuroinflammation | Issue 1/2022

Abstract

Neurodegenerative diseases are a group of disorders characterized by progressive loss of certain populations of neurons, which eventually lead to dysfunction. These diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Immune pathway dysregulation is one of the common features of neurodegeneration. Recently, there is growing interest in the specific role of T helper Th 17 cells and Interleukin-17A (IL-17A), the most important cytokine of Th 17 cells, in the pathogenesis of the central nervous system (CNS) of neurodegenerative diseases. In the present study, we summarized current knowledge about the function of Th17/IL-17A, the physiology of Th17/IL-17A in diseases, and the contribution of Th17/IL-17A in AD, PD, and ALS. We also update the findings on IL-17A-targeting drugs as potentially immunomodulatory therapeutic agents for neurodegenerative diseases. Although the specific mechanism of Th17/IL-17A in this group of diseases is still controversial, uncovering the molecular pathways of Th17/IL-17A in neurodegeneration allows the identification of suitable targets to modulate these cellular processes. Therapeutics targeting IL-17A might represent potentially novel anti-neurodegeneration drugs.

Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50(4):955–74. https://doi.org/10.1016/j.immuni.2019.03.016.CrossRefPubMedPubMedCentral

Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777–83. https://doi.org/10.1126/science.aag2590.CrossRefPubMed

Chen J, Liu X, Zhong Y. Interleukin-17A: the key cytokine in neurodegenerative diseases. Front Aging Neurosci. 2020;12:566922. https://doi.org/10.3389/fnagi.2020.566922 (Published 2020 Sep 29).CrossRefPubMedPubMedCentral

Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32. https://doi.org/10.1038/ni1254.CrossRefPubMed

Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41. https://doi.org/10.1038/ni1261.CrossRefPubMedPubMedCentral

Lee JY, Hall JA, Kroehling L, et al. Serum Amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease [published correction appears in Cell. 2020;183(7):2036–9]. Cell. 2020;180(1):79-91.e16. https://doi.org/10.1016/j.cell.2019.11.026.CrossRefPubMed

Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–8. https://doi.org/10.1038/nature04753.CrossRefPubMed

Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441(7090):231–4. https://doi.org/10.1038/nature04754.CrossRefPubMed

Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179–89. https://doi.org/10.1016/j.immuni.2006.01.001.CrossRefPubMed

10.

Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967–74. https://doi.org/10.1038/ni1488.CrossRefPubMed

11.

Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009;30(4):576–87. https://doi.org/10.1016/j.immuni.2009.02.007.CrossRefPubMedPubMedCentral

12.

Hirota K, Duarte JH, Veldhoen M, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011;12(3):255–63. https://doi.org/10.1038/ni.1993.CrossRefPubMedPubMedCentral

13.

Komuczki J, Tuzlak S, Friebel E, et al. Fate-mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1β. Immunity. 2019;50(5):1289-1304.e6. https://doi.org/10.1016/j.immuni.2019.04.006.CrossRefPubMed

14.

McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314–24. https://doi.org/10.1038/ni.1698.CrossRefPubMedPubMedCentral

15.

Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–33. https://doi.org/10.1016/j.cell.2006.07.035.CrossRefPubMed

16.

Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28(1):29–39. https://doi.org/10.1016/j.immuni.2007.11.016.CrossRefPubMed

17.

Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95–8. https://doi.org/10.1126/science.8140422.CrossRefPubMed

18.

Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice [published correction appears in J Immunol. 2015;194(7):3526]. J Immunol. 1998;161(9):4652–60.PubMed

19.

Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282(13):9358–63. https://doi.org/10.1074/jbc.C600321200.CrossRefPubMed

20.

Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371–81. https://doi.org/10.1016/j.immuni.2007.02.009.CrossRefPubMed

21.

Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature. 2010;467(7318):967–71. https://doi.org/10.1038/nature09447.CrossRefPubMedPubMedCentral

22.

Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650–7. https://doi.org/10.1038/ni.1613.CrossRefPubMed

23.

McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906. https://doi.org/10.1016/j.immuni.2019.03.021.CrossRefPubMedPubMedCentral

24.

Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445–56.PubMed

25.

Gaffen SL. Life before seventeen: cloning of the IL-17 receptor. J Immunol. 2011;187(9):4389–91. https://doi.org/10.4049/jimmunol.1102576.CrossRefPubMed

26.

Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system [published correction appears in Nat Rev Immunol. 2010;10(8):611] [published correction appears in Nat Rev Immunol. 2010;10(7):following 489]. Nat Rev Immunol. 2010;10(7):479–89. https://doi.org/10.1038/nri2800.CrossRefPubMed

27.

Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60. https://doi.org/10.1038/emi.2013.58.CrossRefPubMedPubMedCentral

28.

Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 2010;21(6):413–23. https://doi.org/10.1016/j.cytogfr.2010.10.002.CrossRefPubMedPubMedCentral

29.

Hatfield JK, Brown MA. Group 3 innate lymphoid cells accumulate and exhibit disease-induced activation in the meninges in EAE. Cell Immunol. 2015;297(2):69–79. https://doi.org/10.1016/j.cellimm.2015.06.006.CrossRefPubMed

30.

Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F. T helper cells plasticity in inflammation. Cytometry A. 2014;85(1):36–42. https://doi.org/10.1002/cyto.a.22348.CrossRefPubMed

31.

Cosmi L, Santarlasci V, Maggi L, Liotta F, Annunziato F. Th17 plasticity: pathophysiology and treatment of chronic inflammatory disorders. Curr Opin Pharmacol. 2014;17:12–6. https://doi.org/10.1016/j.coph.2014.06.004.CrossRefPubMed

32.

Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311–21. https://doi.org/10.1111/j.1365-2567.2009.03240.x.CrossRefPubMedPubMedCentral

33.

Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600. https://doi.org/10.1038/nri3707.CrossRefPubMedPubMedCentral

34.

Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195(3):780–8. https://doi.org/10.4049/jimmunol.1500909.CrossRefPubMed

35.

Drummond RA, Lionakis MS. Organ-specific mechanisms linking innate and adaptive antifungal immunity. Semin Cell Dev Biol. 2019;89:78–90. https://doi.org/10.1016/j.semcdb.2018.01.008.CrossRefPubMed

36.

Naik S, Bouladoux N, Linehan JL, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015;520(7545):104–8. https://doi.org/10.1038/nature14052.CrossRefPubMedPubMedCentral

37.

Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485–98. https://doi.org/10.1016/j.cell.2009.09.033.CrossRefPubMedPubMedCentral

38.

Kumar P, Monin L, Castillo P, et al. Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity. 2016;44(3):659–71. https://doi.org/10.1016/j.immuni.2016.02.007.CrossRefPubMedPubMedCentral

39.

Phuna ZX, Madhavan P. A closer look at the mycobiome in Alzheimer’s disease: fungal species, pathogenesis and transmission. Eur J Neurosci. 2022;55(5):1291–321. https://doi.org/10.1111/ejn.15599.CrossRefPubMed

40.

Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181(1):8–18. https://doi.org/10.1016/j.ajpath.2012.03.044.CrossRefPubMed

41.

Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993–1005. https://doi.org/10.1517/13543784.2013.806483.CrossRefPubMed

42.

Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48. https://doi.org/10.1056/NEJMoa1505066.CrossRefPubMed

43.

Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647–56. https://doi.org/10.1002/art.24568.CrossRefPubMed

44.

Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol. 2015;42(6):912–9. https://doi.org/10.3899/jrheum.141271.CrossRefPubMed

45.

Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472–83. https://doi.org/10.1002/art.24499.CrossRefPubMed

46.

Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009;15(5):199–207. https://doi.org/10.1016/j.molmed.2009.03.002.CrossRefPubMed

47.

Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9(6):641–9. https://doi.org/10.1038/ni.1610.CrossRefPubMedPubMedCentral

48.

Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8(5):500–8. https://doi.org/10.1038/nm0502-500.CrossRefPubMed

49.

Schofield C, Fischer SK, Townsend MJ, et al. Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis. Bioanalysis. 2016;8(22):2317–27. https://doi.org/10.4155/bio-2016-0207.CrossRefPubMed

50.

Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis [published correction appears in Immunology. 2008;125(3):438]. Immunology. 2008;125(2):161–9. https://doi.org/10.1111/j.1365-2567.2008.02837.x.CrossRefPubMedPubMedCentral

51.

Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009;132(Pt 12):3329–41. https://doi.org/10.1093/brain/awp289.CrossRefPubMed

52.

Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65(5):499–509. https://doi.org/10.1002/ana.21652.CrossRefPubMed

53.

Setiadi AF, Abbas AR, Jeet S, et al. IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2019;332:147–54. https://doi.org/10.1016/j.jneuroim.2019.04.011.CrossRefPubMed

54.

Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta Neuropathol. 2015;129(5):625–37. https://doi.org/10.1007/s00401-015-1402-7.CrossRefPubMed

55.

Huppert J, Closhen D, Croxford A, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2010;24(4):1023–34. https://doi.org/10.1096/fj.09-141978.CrossRefPubMed

56.

Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173–5. https://doi.org/10.1038/nm1651.CrossRefPubMedPubMedCentral

57.

Tahmasebinia F, Pourgholaminejad A. The role of Th17 cells in auto-inflammatory neurological disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):408–16. https://doi.org/10.1016/j.pnpbp.2017.07.023.CrossRefPubMed

58.

Prajeeth CK, Kronisch J, Khorooshi R, et al. Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties. J Neuroinflamm. 2017;14(1):204. https://doi.org/10.1186/s12974-017-0978-3 (Published 2017 Oct 16).CrossRef

59.

Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24(4):641–51. https://doi.org/10.1016/j.bbi.2010.01.014.CrossRefPubMed

60.

Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233–40. https://doi.org/10.1084/jem.20041257.CrossRefPubMedPubMedCentral

61.

Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146–55. https://doi.org/10.2353/ajpath.2008.070690.CrossRefPubMedPubMedCentral

62.

Segal BM. Th17 cells in autoimmune demyelinating disease. Semin Immunopathol. 2010;32(1):71–7. https://doi.org/10.1007/s00281-009-0186-z.CrossRefPubMedPubMedCentral

63.

Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177(1):566–73. https://doi.org/10.4049/jimmunol.177.1.566.CrossRefPubMed

64.

Havrdová E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287–95. https://doi.org/10.1007/s00415-016-8128-x.CrossRefPubMed

65.

Sun J, Zhang S, Zhang X, Zhang X, Dong H, Qian Y. IL-17A is implicated in lipopolysaccharide-induced neuroinflammation and cognitive impairment in aged rats via microglial activation. J Neuroinflamm. 2015;12:165. https://doi.org/10.1186/s12974-015-0394-5 (Published 2015 Sep 15).CrossRef

66.

Cristiano C, Volpicelli F, Lippiello P, et al. Neutralization of IL-17 rescues amyloid-β-induced neuroinflammation and memory impairment. Br J Pharmacol. 2019;176(18):3544–57. https://doi.org/10.1111/bph.14586.CrossRefPubMedPubMedCentral

67.

Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson’s disease [published correction appears in Cell Stem Cell. 2019 Jun 6;24(6):1006]. Cell Stem Cell. 2018;23(1):123-131.e6. https://doi.org/10.1016/j.stem.2018.06.015.CrossRefPubMed

68.

Liu Z, Qiu AW, Huang Y, et al. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson’s disease. Brain Behav Immun. 2019;81:630–45. https://doi.org/10.1016/j.bbi.2019.07.026.CrossRefPubMed

69.

Liu Z, Huang Y, Cao BB, Qiu YH, Peng YP. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of parkinson’s disease. Mol Neurobiol. 2017;54(10):7762–76. https://doi.org/10.1007/s12035-016-0249-9.CrossRefPubMed

70.

Jin M, Akgün K, Ziemssen T, Kipp M, Günther R, Hermann A. Interleukin-17 and Th17 lymphocytes directly impair motoneuron survival of wildtype and FUS-ALS mutant human iPSCs. Int J Mol Sci. 2021;22(15):8042. https://doi.org/10.3390/ijms22158042 (Published 2021 Jul 27).CrossRefPubMedPubMedCentral

71.

Yan XZ, Lai L, Ao Q, Tian XH, Zhang YH. Interleukin-17A in Alzheimer’s disease: recent advances and controversies. Curr Neuropharmacol. 2022;20(2):372–83. https://doi.org/10.2174/1570159X19666210823110004.CrossRefPubMed

72.

Taipa R, das Neves SP, Sousa AL, et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol Aging. 2019;76:125–32. https://doi.org/10.1016/j.neurobiolaging.2018.12.019.CrossRefPubMed

73.

Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69(10):1318–25. https://doi.org/10.1001/archneurol.2012.1282.CrossRefPubMedPubMedCentral

74.

Hu WT, Chen-Plotkin A, Grossman M, et al. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology. 2010;75(23):2079–86. https://doi.org/10.1212/WNL.0b013e318200d78d.CrossRefPubMedPubMedCentral

75.

Zenaro E, Pietronigro E, Della Bianca V, et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880–6. https://doi.org/10.1038/nm.3913.CrossRefPubMed

76.

Browne TC, McQuillan K, McManus RM, O’Reilly JA, Mills KH, Lynch MA. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease. J Immunol. 2013;190(5):2241–51. https://doi.org/10.4049/jimmunol.1200947.CrossRefPubMed

77.

Mohammadi Shahrokhi V, Ravari A, Mirzaei T, Zare-Bidaki M, Asadikaram G, Arababadi MK. IL-17A and IL-23: plausible risk factors to induce age-associated inflammation in Alzheimer’s disease. Immunol Invest. 2018;47(8):812–22. https://doi.org/10.1080/08820139.2018.1504300.CrossRefPubMed

78.

Yin Y, Wen S, Li G, Wang D. Hypoxia enhances stimulating effect of amyloid beta peptide (25–35) for interleukin 17 and T helper lymphocyte subtype 17 upregulation in cultured peripheral blood mononuclear cells. Microbiol Immunol. 2009;53(5):281–6. https://doi.org/10.1111/j.1348-0421.2009.00120.x.CrossRefPubMed

79.

Machhi J, Yeapuri P, Lu Y, et al. CD4+ effector T cells accelerate Alzheimer’s disease in mice. J Neuroinflamm. 2021;18(1):272. https://doi.org/10.1186/s12974-021-02308-7 (Published 2021 Nov 19).CrossRef

80.

Sun L, Ju T, Wang T, et al. Decreased Netrin-1 and correlated Th17/Tregs balance disorder in Aβ1–42 induced alzheimer’s disease model rats. Front Aging Neurosci. 2019;11:124. https://doi.org/10.3389/fnagi.2019.00124 (Published 2021 Nov 19).CrossRefPubMedPubMedCentral

81.

Knopp RC, Baumann KK, Wilson ML, Banks WA, Erickson MA. Amyloid Beta pathology exacerbates weight loss and brain cytokine responses following low-dose lipopolysaccharide in aged female Tg2576 mice. Int J Mol Sci. 2022;23(4):2377. https://doi.org/10.3390/ijms23042377 (Published 2022 Feb 21).CrossRefPubMedPubMedCentral

82.

Milovanovic J, Arsenijevic A, Stojanovic B, et al. Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol. 2020;11:947. https://doi.org/10.3389/fimmu.2020.00947 (Published 2020 Jun 3).CrossRefPubMedPubMedCentral

83.

Wang X, Zhang M, Liu H. LncRNA17A regulates autophagy and apoptosis of SH-SY5Y cell line as an in vitro model for Alzheimer’s disease. Biosci Biotechnol Biochem. 2019;83(4):609–21. https://doi.org/10.1080/09168451.2018.1562874.CrossRefPubMed

84.

Xie Z, Lu H, Yang S, et al. Salidroside attenuates cognitive dysfunction in senescence-accelerated mouse prone 8 (SAMP8) mice and modulates inflammation of the gut-brain axis. Front Pharmacol. 2020;11:568423. https://doi.org/10.3389/fphar.2020.568423 (Published 2020 Dec 9).CrossRefPubMedPubMedCentral

85.

Derkow K, Krüger C, Dembny P, Lehnardt S. Microglia induce neurotoxic IL-17+ γδ T cells dependent on TLR2, TLR4, and TLR9 activation. PLoS ONE. 2015;10(8):e0135898. https://doi.org/10.1371/journal.pone.0135898 (Published 2015 Aug 19).CrossRefPubMedPubMedCentral

86.

Gu Y, Wu Z, Zeng F, et al. Systemic exposure to lipopolysaccharide from porphyromonas gingivalis induces bone loss-correlated Alzheimer’s disease-like pathologies in middle-aged mice. J Alzheimers Dis. 2020;78(1):61–74. https://doi.org/10.3233/JAD-200689.CrossRefPubMed

87.

Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of ab1-42-induced Alzheimer’s disease model rats. PLoS ONE. 2013;8:e75786. https://doi.org/10.1371/journal.pone.0075786.CrossRefPubMedPubMedCentral

88.

St-Amour I, Bosoi CR, Paré I, et al. Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer’s disease. J Neuroinflamm. 2019;16(1):3. https://doi.org/10.1186/s12974-018-1380-5 (Published 2019 Jan 5).CrossRef

89.

Lemprière S. T cells on patrol in Alzheimer disease. Nat Rev Neurol. 2020;16(3):128–9. https://doi.org/10.1038/s41582-020-0317-7.CrossRefPubMed

90.

Saresella M, Calabrese E, Marventano I, et al. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer’s disease. Brain Behav Immun. 2011;25(3):539–47. https://doi.org/10.1016/j.bbi.2010.12.004.CrossRefPubMed

91.

Oberstein TJ, Taha L, Spitzer P, et al. Imbalance of circulating Th17 and regulatory T cells in Alzheimer’s disease: a case control study. Front Immunol. 2018;9:1213. https://doi.org/10.3389/fimmu.2018.01213 (Published 2018 Jun 4).CrossRefPubMedPubMedCentral

92.

Saksida T, Koprivica I, Vujičić M, et al. Impaired IL-17 production in gut-residing immune cells of 5xFAD mice with Alzheimer’s Disease pathology. J Alzheimers Dis. 2018;61(2):619–30. https://doi.org/10.3233/JAD-170538.CrossRefPubMed

93.

McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 mice. Neurobiol Aging. 2014;35(1):109–21. https://doi.org/10.1016/j.neurobiolaging.2013.07.025.CrossRefPubMed

94.

Ahuja M, Buabeid M, Abdel-Rahman E, et al. Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer’s disease. Life Sci. 2017;177:49–59. https://doi.org/10.1016/j.lfs.2017.03.004.CrossRefPubMed

95.

Zeng J, Liu J, Qu Q, Zhao X, Zhang J. JKAP, Th1 cells, and Th17 cells are dysregulated and inter-correlated, among them JKAP and Th17 cells relate to cognitive impairment progression in Alzheimer’s disease patients [published online ahead of print, 2021 Sep 30]. Ir J Med Sci. 2021. https://doi.org/10.1007/s11845-021-02749-2.CrossRefPubMed

96.

Zhang Y, Wang X, Yang X, Yang X, Xue J, Yang Y. Ganoderic acid A to alleviate neuroinflammation of Alzheimer’s disease in mice by regulating the imbalance of the Th17/Tregs axis. J Agric Food Chem. 2021;69(47):14204–14. https://doi.org/10.1021/acs.jafc.1c06304.CrossRefPubMed

97.

Chen Y, Qi Z, Qiao B, Lv Z, Hao Y, Li H. Oxymatrine can attenuate pathological deficits of Alzheimer’s disease mice through regulation of neuroinflammation. J Neuroimmunol. 2019;334:576978. https://doi.org/10.1016/j.jneuroim.2019.576978.CrossRefPubMed

98.

Fragoulis A, Siegl S, Fendt M, et al. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer’s disease. Redox Biol. 2017;12:843–53. https://doi.org/10.1016/j.redox.2017.04.024.CrossRefPubMedPubMedCentral

99.

Katayama H. Anti-interleukin-17A and anti-interleukin-23 antibodies may be effective against Alzheimer’s disease: role of neutrophils in the pathogenesis. Brain Behav. 2020;10(1):e01504. https://doi.org/10.1002/brb3.1504.CrossRefPubMed

100.

Marciani DJ. Alzheimer’s disease vaccine development: a new strategy focusing on immune modulation. J Neuroimmunol. 2015;287:54–63. https://doi.org/10.1016/j.jneuroim.2015.08.008.CrossRefPubMed

101.

Kubick N, Flournoy PCH, Enciu AM, Manda G, Mickael ME. Drugs modulating CD4+ T cells blood-brain barrier interaction in Alzheimer’s disease. Pharmaceutics. 2020;12(9):880. https://doi.org/10.3390/pharmaceutics12090880.CrossRefPubMedCentral

102.

Yang J, Kou J, Lalonde R, Fukuchi KI. Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer’s disease. Brain Behav Immun. 2017;65:262–73. https://doi.org/10.1016/j.bbi.2017.05.012.CrossRefPubMedPubMedCentral

103.

Tfilin M, Turgeman G. Interleukine-17 administration modulates adult hippocampal neurogenesis and improves spatial learning in mice. J Mol Neurosci. 2019;69(2):254–63. https://doi.org/10.1007/s12031-019-01354-4.CrossRefPubMed

104.

Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol. 2005;62(3):353–7. https://doi.org/10.1001/archneur.62.3.353.CrossRefPubMed

105.

Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord. 2011;26(6):1049–55. https://doi.org/10.1002/mds.23732.CrossRefPubMed

106.

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. https://doi.org/10.1016/S0140-6736(14)61393-3.CrossRefPubMed

107.

Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14(8):855–66. https://doi.org/10.1016/S1474-4422(15)00006-X.CrossRefPubMedPubMedCentral

108.

More SV, Kumar H, Kim IS, Song SY, Choi DK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators Inflamm. 2013;2013:952375. https://doi.org/10.1155/2013/952375.CrossRefPubMedPubMedCentral

109.

McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(Suppl 1):S3–7. https://doi.org/10.1016/j.parkreldis.2004.01.005.CrossRefPubMed

110.

Kustrimovic N, Comi C, Magistrelli L, et al. Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J Neuroinflamm. 2018;15(1):205. https://doi.org/10.1186/s12974-018-1248-8 (Published 2018 Jul 12).CrossRef

111.

Niwa F, Kuriyama N, Nakagawa M, Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson’s disease. Geriatr Gerontol Int. 2012;12(1):102–7. https://doi.org/10.1111/j.1447-0594.2011.00740.x.CrossRefPubMed

112.

Cook DA, Kannarkat GT, Cintron AF, et al. LRRK2 levels in immune cells are increased in Parkinson’s disease. NPJ Parkinsons Dis. 2017;3:11. https://doi.org/10.1038/s41531-017-0010-8 (Published 2017 Mar 28).CrossRefPubMedPubMedCentral

113.

Chen Y, Qi B, Xu W, et al. Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson’s disease. Mol Med Rep. 2015;12(4):6105–11. https://doi.org/10.3892/mmr.2015.4136.CrossRefPubMed

114.

Yang F, Li B, Li L, Zhang H. The clinical significance of the imbalance of Th17 and Treg cells and their related cytokines in peripheral blood of Parkinson’s disease patients. Int J Clin Exp Med. 2016;9:17946–51.

115.

Cen L, Yang C, Huang S, et al. Peripheral lymphocyte subsets as a marker of Parkinson’s disease in a Chinese population. Neurosci Bull. 2017;33(5):493–500. https://doi.org/10.1007/s12264-017-0163-9.CrossRefPubMedPubMedCentral

116.

Yang L, Guo C, Zhu J, et al. Increased levels of pro-inflammatory and anti-inflammatory cellular responses in Parkinson’s disease patients: search for a disease indicator. Med Sci Monit. 2017;23:2972–8. https://doi.org/10.12659/msm.904240 (Published 2017 Jun 18).CrossRefPubMedPubMedCentral

117.

Storelli E, Cassina N, Rasini E, Marino F, Cosentino M. Do Th17 lymphocytes and IL-17 contribute to Parkinson’s disease? A systematic review of available evidence. Front Neurol. 2019;10:13. https://doi.org/10.3389/fneur.2019.00013 (Published 2019 Jan 24).CrossRefPubMedPubMedCentral

118.

Rocha NP, Assis F, Scalzo PL, et al. Reduced activated T lymphocytes (CD4+CD25+) and plasma levels of cytokines in Parkinson’s disease. Mol Neurobiol. 2018;55(2):1488–97. https://doi.org/10.1007/s12035-017-0404-y.CrossRefPubMed

119.

Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, et al. Regulatory impairment in untreated Parkinson’s disease is not restricted to Tregs: other regulatory populations are also involved. J Neuroinflamm. 2019;16(1):212. https://doi.org/10.1186/s12974-019-1606-1 (Published 2019 Nov 11).CrossRef

120.

Liu L, Li Y, Peng H, et al. Targeted exosome coating gene-chem nanocomplex as “nanoscavenger” for clearing α-synuclein and immune activation of Parkinson’s disease. Sci Adv. 2020;6(50):eaba3967. https://doi.org/10.1126/sciadv.aba3967 (Published 2020 Dec 11).CrossRefPubMedPubMedCentral

121.

Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S210–2. https://doi.org/10.1016/S1353-8020(11)70065-7.CrossRefPubMed

122.

Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57(2):176–9. https://doi.org/10.1002/ana.20369.CrossRefPubMed

123.

Liu Z, Zhai XR, Du ZS, et al. Dopamine receptor D2 on CD4+ T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease. Brain Behav Immun. 2021;98:110–21. https://doi.org/10.1016/j.bbi.2021.08.220.CrossRefPubMed

124.

Elgueta D, Contreras F, Prado C, et al. Dopamine receptor D3 expression is altered in CD4+ T cells from Parkinson’s disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front Immunol. 2019;10:981. https://doi.org/10.3389/fimmu.2019.00981 (Published 2019 May 1).CrossRefPubMedPubMedCentral

125.

Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76(3):315–25. https://doi.org/10.1111/j.1365-2265.2011.04261.x.CrossRef

126.

Ooi JH, Chen J, Cantorna MT. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med. 2012;33(1):77–82. https://doi.org/10.1016/j.mam.2011.10.014.CrossRefPubMed

127.

Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients. 2015;7(4):3011–21. https://doi.org/10.3390/nu7043011 (Published 2015 Apr 22).CrossRefPubMedPubMedCentral

128.

Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–71. https://doi.org/10.4049/jimmunol.0901852.CrossRefPubMed

129.

Prots I, Winner B. Th17 cells: a promising therapeutic target for Parkinson’s disease? Expert Opin Ther Targets. 2019;23(4):309–14. https://doi.org/10.1080/14728222.2019.1590336.CrossRefPubMed

130.

Feng YK, Wu QL, Peng YW, et al. Oral P gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. J Neuroinflamm. 2020;17(1):347. https://doi.org/10.1186/s12974-020-02027-5 (Published 2020 Nov 19).CrossRef

131.

Jiang Y, Cao Z, Ma H, et al. Auricular vagus nerve stimulation exerts antiinflammatory effects and immune regulatory function in a 6-OHDA model of Parkinson’s disease. Neurochem Res. 2018;43(11):2155–64. https://doi.org/10.1007/s11064-018-2639-z.CrossRefPubMed

132.

Kim KH, Lee SY, Shin J, Hwang JT, Jeon HN, Bae H. Dose-dependent neuroprotective effect of standardized bee venom phospholipase A2 against MPTP-induced Parkinson’s disease in mice. Front Aging Neurosci. 2019;11:80. https://doi.org/10.3389/fnagi.2019.00080 (Published 2019 Apr 5).CrossRefPubMedPubMedCentral

133.

Yang Q, Zhuang J, Cai P, Li L, Wang R, Chen Z. JKAP relates to disease risk, severity, and Th1 and Th17 differentiation in Parkinson’s disease. Ann Clin Transl Neurol. 2021;8(9):1786–95. https://doi.org/10.1002/acn3.51420.CrossRefPubMedPubMedCentral

134.

Aftanas LI, Gevorgyan MM, Zhanaeva SY, et al. Therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) on neuroinflammation and neuroplasticity in patients with Parkinson’s disease: a placebo-controlled study. Bull Exp Biol Med. 2018;165(2):195–9. https://doi.org/10.1007/s10517-018-4128-4.CrossRefPubMed

135.

MacMahon Copas AN, McComish SF, Fletcher JM, Caldwell MA. The pathogenesis of Parkinson’s disease: a complex interplay between astrocytes, microglia, and T lymphocytes? Front Neurol. 2021;12:666737. https://doi.org/10.3389/fneur.2021.666737 (Published 2021 May 26).CrossRefPubMedPubMedCentral

136.

Tian Y, Cao Y, Chen R, et al. HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson’s disease model. Clin Sci (Lond). 2020;134(15):2075–90. https://doi.org/10.1042/CS20200553.CrossRef

137.

Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6):1469-1480.e12. https://doi.org/10.1016/j.cell.2016.11.018.CrossRefPubMedPubMedCentral

138.

Cui G, Qin X, Wu L, et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest. 2011;121(2):658–70. https://doi.org/10.1172/JCI42974.CrossRefPubMedPubMedCentral

139.

Klotz L, Burgdorf S, Dani I, et al. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity [published correction appears in J Exp Med. 2009 Dec 21;206(13):3159. Novak, Natalija [corrected to Nowak, Nina]]. J Exp Med. 2009;206(10):2079–89. https://doi.org/10.1084/jem.20082771.CrossRefPubMedPubMedCentral

140.

Carta AR. PPAR-γ: therapeutic prospects in Parkinson’s disease. Curr Drug Targets. 2013;14(7):743–51. https://doi.org/10.2174/1389450111314070004.CrossRefPubMed

141.

Rentzos M, Rombos A, Nikolaou C, et al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand. 2010;122(6):425–9. https://doi.org/10.1111/j.1600-0404.2010.01333.x.CrossRefPubMed

142.

Saresella M, Piancone F, Tortorella P, et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148(1):79–88. https://doi.org/10.1016/j.clim.2013.04.010.CrossRefPubMed

143.

Jin M, Günther R, Akgün K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941. https://doi.org/10.1038/s41598-020-62756-8 (Published 2020 Apr 3).CrossRefPubMedPubMedCentral

144.

Fiala M, Chattopadhay M, La Cava A, et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflamm. 2010;7:76. https://doi.org/10.1186/1742-2094-7-76 (Published 2010 Nov 9).CrossRef

145.

Chen X, Feng W, Ou R, et al. Evidence for peripheral immune activation in Parkinson’s disease. Front Aging Neurosci. 2021;13:617370. https://doi.org/10.3389/fnagi.2021.617370 (Published 2021 Apr 30).CrossRefPubMedPubMedCentral

Title: The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
Authors: Jiajia Fu
Yan Huang
Ting Bao
Chengcheng Liu
Xi Liu
Xueping Chen
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Amyotrophic Lateral Sclerosis
Alzheimer's Disease
Targeted Therapy
Alzheimer's Disease
Parkinson's Disease
Cytokines
Published in: Journal of Neuroinflammation / Issue 1/2022
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-022-02446-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

The effects of splenectomy in murine models of ischemic stroke: a systematic review and meta-analysis

Potential biomarkers of spinal dural arteriovenous fistula: C4BPA and C1QA

Motor neuron survival is associated with reduced neuroinflammation and increased autophagy after brachial plexus avulsion injury in aldose reductase-deficient mice

Phagocytosis converts infiltrated monocytes to microglia-like phenotype in experimental brain ischemia

Repopulated microglia induce expression of Cxcl13 with differential changes in Tau phosphorylation but do not impact amyloid pathology

Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid